Skip to main content
SpringerLink
Log in

Construction and anti-tumor effects of recombinant fowlpox virus expressing Newcastle disease virus hemagglutinin-neuramidinase gene

  • Articles
  • Published:
Chinese Science Bulletin

Abstract

Hemagglutinin-neuramidinase (HN), a Newcastle disease virus-derived protein, not only mediates receptor recognition but also possesses neuraminidase (NA) activity, the ability to cleave a component of those receptors, N-acetylneuraminic acid (NAcneu, sialic acid). It is known that this protein in mammalian species, including human beings, has interesting anti-neoplastic as well as immune stimulating properties. To explore the use of the HN gene in cancer gene therapy, we constructed a recombinant fowlpox virus expressing the HN protein (vFV-HN) and compared the anti-tumor activity of the recombinant virus with that of wild-type fowlpox virus (FPV) in vivo and in vitro. Here we found that although B16 cells were somewhat resistant to the basal cytotoxic effect of wild-type fowlpox virus, infection with vFV-HN caused a pronounced cytotoxic effect and, the survival of tumor-bearing mice immunized with vFV-HN was significantly increased compared with the survival of mice immunized with the FPV alone. Furthermore, the immunization of mice with vFV-HN elicited a B16 tumor-specific cytotoxic T lymphocyte (CTL) response and clonal expansion of both CD4+ and CD8+ T cell populations in vivo. In addition, T cells from lymph nodes of mice vaccinated with vFV-HN secreted high levels of the Th1 cytokine IL-2 and IFN-γ, indicating that the regression of tumor cells is related to a Th1-type dominant immune response. These results demonstrate that vaccination with vFV-HN may be a potential strategy for cancer gene therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Dziadek S, Espinola C G, Kunz H. Synthetic glycopeptides for the development of antitumor vaccines. Aust J Chem, 2003, 56: 519–543

    Article  Google Scholar 

  2. Haas C, Lulei M, Fournier P, et al. A tumor vaccine containing anti-CD3 and anti-CD28 bispecific antibodies triggers strong and durable antitumor activity in human lymphocytes. Intl J Cancer, 2006, 118(3): 658–667

    Article  Google Scholar 

  3. Mebatsion T, Koolen M J M, de Vaan L T C, et al. Newcastle Disease Virus (NDV) marker vaccine: An immunodominant epitope on the nucleoprotein gene of NDV can be deleted or replaced by a foreign epitope. J Virol, 2002, 76(20): 10138–10146

    Article  Google Scholar 

  4. Schirrmacher V, Haas C, Bonifer R, et al. Human tumor cell modification by virus infection: An efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus. Gene Ther, 1999, 6: 63–73

    Article  Google Scholar 

  5. Bian H, Fournier P, Moormann R, et al. Selective gene transfer to tumor cells by recombinant Newcastle Disease Virus via a bispecific fusion protein. Intl J Oncol, 2005, 26: 431–439

    Google Scholar 

  6. Bian H, Fournier P, Moormann R, et al. Selective gene transfer in vitro to tumor cells via recombinant Newcastle disease virus. Cancer Gene Ther, 2005, 12: 295–303

    Article  Google Scholar 

  7. Schirrmacher V. Clinical trials of antitumor vaccination with an autologous tumor cell vaccine modified by virus infection: Improvement of patient survival based on improved antitumor immune memory. Cancer Immunol Immuneother, 2005, 54: 587–598

    Article  Google Scholar 

  8. Zeng J, Fournier P, Schirrmacher V. Induction of interferon-α and tumor necrosis factor-related apoptosis-inducing ligand in human blood mononuclear cells by Hemagglutinin-Neuraminidase but not F protein of Newcastle Disease Virus. Virology, 2002, 297: 19–30

    Article  Google Scholar 

  9. Li X, Jin N Y, Mi Z Q, et al. The construction of nucleic vaccine expressing apoptin gene, Newcastle disease virus HN gene and IL-18 gene and its antitumor effect on B16. High Technol Lett (in Chinese), 2004, 14(12): 33–36

    Google Scholar 

  10. Jin N Y, Zhang H Y, Zheng M, et al. Immunogenicity of recombinant fowl-pox virus co-expressing structural protein precursor P1-2A and proteinase 3C of FMDV. Chin Sci Bull (in Chinese), 2004, 49(8): 823–827

    Article  Google Scholar 

  11. Jiang W Z, Jin N Y, Cui S F, et al. Construction and characterization of recombinant fowlpox virus coexpressing HIV-1CN gp120 and IL-2. J Virol Methods, 2005, 130(1–2): 95–101

    Article  Google Scholar 

  12. Ribble D, Goldstein N B, Norris D A, et al. A simple technique for quantifying apoptosis in 96-well plates. BMC Biotechnol, 2005, 5: 12

    Article  Google Scholar 

  13. Cao X J, Wang Y M. Serum sialic acid detection with 3,5-dihydroxytoluene. J Clin Test (in Chinese), 1998, 16(3): 153–154

    Google Scholar 

  14. Slavin-Chiorini D C, Catalfamo M, Kudo-Saito C, et al. Amplification of the lytic potential of effector/memory CD8+ cells by vector-based enhancement of ICAM-1 (CD54) in target cells: Implications for intratumoral vaccine therapy. Cancer Gene Ther, 2004, 11: 665–680

    Article  Google Scholar 

  15. Pharoah P D, Dunning A M, Ponder B A, et al. Association studies for finding cancer-susceptibility genetic variants. Cancer, 2004, 11(4): 850–860

    Google Scholar 

  16. Haviv Y S, Curiel D T. Conditional gene targeting for cancer gene therapy. Adv Drug Deliv Rev, 2001, 53: 135–154

    Article  Google Scholar 

  17. El-Aneed A. Current strategies in cancer gene therapy. Eur J Pharmacol, 2004, 498: 1–8

    Article  Google Scholar 

  18. Cassel W A, Garret R E. Newcastle disease virus as an antineoplastic agent. Cancer, 1965, 7: 863–868

    Article  Google Scholar 

  19. Connaris H, Takimoto T, Russell R, et al. Probing the sialic acid binding site of the hemagglutinin-neuraminidase of Newcastle Disease Virus: Identification of key amino acids involved in cell binding, catalysis, and fusion. J Virol, 2002, 76(4): 1816–1824

    Article  Google Scholar 

  20. Iorio R M, Field G M, Sauvron J M, et al. Sauvron,et al. Structural and functional relationship between the receptor recognition and neuraminidase activities of the Newcastle Disease Virus hemagglutinin-neuraminidase protein: Receptor recognition is dependent on neuraminidase activity. J Virol, 2001, 75(4): 1918–1927

    Article  Google Scholar 

  21. McGinnes L W, Gravel K, Morrison, T G. Newcastle Disease Virus HN protein alters the conformation of the F protein at cell surfaces. J Virol, 2002, 76(24): 12622–12633

    Article  Google Scholar 

  22. Washburn B, Weigand M A, Grosse-Wilde A, et al. TNF-related apoptosis-inducing ligand mediates tumoricidal activity of human monocytes stimulated by Newcastle Disease Virus. J Immunol, 2003, 170: 1814–1821

    Google Scholar 

  23. Mahnke Y D, Schirrmacher V. A novel tumor model system for the study of long-term protective immunity and immune T cell memory. Cell Immunol, 2003, 221: 89–99

    Article  Google Scholar 

  24. Washburn B, Schirrmacher V. Human tumor cell infection by Newcastle disease virus leads to upregulation of HLA and cell adhesion molecules and to induction of interferons, chemokines and finally apoptosis. Intl J Oncol, 2002, 21: 85–93

    Google Scholar 

  25. Webster D P, Dunachie S, McConkey S, et al. Safety of recombinant fowlpox strain FP9 and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers. Vaccine, 2006, 24: 3026–3034

    Article  Google Scholar 

  26. Marshall J L, Gulley J L, Arlen P M, et al. Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas. J Clin Oncol, 2005, 23: 720–731

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Genetic Engineering Laboratory of PLA, The Eleventh Institute of Academy of Military Medical Sciences of PLA, Changchun, 130062, China

    Li Xiao, Jin Ningyi, Lian Hai, Li Xuemei & Zheng Hongling

  2. Faculty of Agriculture Sciences of Jilin University, Changchun, 130062, China

    Li Xiao

  3. The Second Hospital, Bethune Faculty of Medical Sciences of Jilin University, Changchun, 130041, China

    Guan Goufang & Sun Lili

Authors
  1. Li Xiao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jin Ningyi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lian Hai
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Guan Goufang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sun Lili
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Li Xuemei
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Zheng Hongling
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jin Ningyi.

About this article

Cite this article

Li, X., Jin, N., Lian, H. et al. Construction and anti-tumor effects of recombinant fowlpox virus expressing Newcastle disease virus hemagglutinin-neuramidinase gene. CHINESE SCI BULL 51, 2724–2730 (2006). https://doi.org/10.1007/s11434-006-2176-z

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11434-006-2176-z

Keywords

Search

Navigation